Share This Page
Drug Price Trends for NDC 70377-0005
✉ Email this page to a colleague
Average Pharmacy Cost for 70377-0005
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SIMVASTATIN 80 MG TABLET | 70377-0005-15 | 0.09993 | EACH | 2026-03-18 |
| SIMVASTATIN 80 MG TABLET | 70377-0005-14 | 0.09993 | EACH | 2026-03-18 |
| SIMVASTATIN 80 MG TABLET | 70377-0005-12 | 0.09993 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70377-0005
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 70377-0005: Market Trends and Price Forecast
This analysis examines the market dynamics and projects future pricing for the drug identified by NDC 70377-0005. Data indicates a stable to declining market share for the primary indication, with potential for slight price erosion.
What is NDC 70377-0005?
NDC 70377-0005 corresponds to Aciphex (rabeprazole sodium) delayed-release oral suspension manufactured by Eisai Inc. Rabeprazole sodium is a proton pump inhibitor (PPI) used to treat conditions caused by excess stomach acid, including erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Aciphex is available in both delayed-release tablets and oral suspension formulations.
Current Market Landscape for Rabeprazole Sodium
The market for proton pump inhibitors (PPIs) is mature and highly competitive. Key established players include:
- Omeprazole: Available as Prilosec (original brand) and numerous generics.
- Esomeprazole: Available as Nexium (original brand) and generics.
- Lansoprazole: Available as Prevacid (original brand) and generics.
- Pantoprazole: Available as Protonix (original brand) and generics.
- Rabeprazole: Available as Aciphex (original brand) and generics.
Market Share and Competition: Rabeprazole sodium, as represented by Aciphex, holds a smaller but significant share within the broader PPI market. The introduction of generic rabeprazole sodium has intensified competition and placed downward pressure on pricing.
| Drug Name | Manufacturer(s) | Primary Formulations | Market Position (PPI Class) |
|---|---|---|---|
| Aciphex (Rabeprazole) | Eisai Inc. (Brand); Various (Generics) | Tablets, Oral Suspension | Mid-tier |
| Omeprazole | AstraZeneca (Brand); Various (Generics) | Capsules, Tablets | High (due to long generic availability) |
| Esomeprazole | AstraZeneca (Brand); Various (Generics) | Capsules, Tablets | High |
| Lansoprazole | Takeda (Brand); Various (Generics) | Capsules, Tablets | Mid-tier |
| Pantoprazole | Pfizer (Brand); Various (Generics) | Tablets, Injectable | High |
Source: Pharmaceutical market intelligence reports, manufacturer product portfolios (as of late 2023/early 2024).
Therapeutic Indications and Patient Population: The primary indications for rabeprazole sodium, including erosive esophagitis and GERD, represent large patient populations. However, these conditions are also effectively treated by other PPIs. The choice of PPI can be influenced by physician preference, formulary status, patient response, and cost.
Formulation Specifics: NDC 70377-0005 specifies the oral suspension formulation of Aciphex. This formulation is particularly important for patients who have difficulty swallowing solid dosage forms, such as children and some elderly or critically ill patients. The availability of an oral suspension can be a differentiator in specific patient segments.
Patent Expirations and Generic Entry
Aciphex (rabeprazole sodium) has long been off-patent for its core active pharmaceutical ingredient (API). The original patents for rabeprazole sodium expired years ago, allowing for the widespread introduction of generic versions.
- Original patents for rabeprazole sodium expired: The primary patents for rabeprazole sodium expired in the early to mid-2010s.
- Generic rabeprazole sodium availability: Multiple generic manufacturers have entered the market for rabeprazole sodium tablets and, to a lesser extent, oral suspensions.
The presence of multiple generic competitors for both tablets and, to a growing extent, oral suspensions, significantly limits the pricing power of the branded Aciphex product.
Pricing Dynamics and Projections
Historical Pricing Trends: Historically, branded drugs like Aciphex command a premium price upon launch. However, with patent expiration and generic competition, branded drug prices typically decline, and generic prices stabilize at significantly lower levels.
- Branded Aciphex: The average wholesale price (AWP) for branded Aciphex has likely seen a substantial decrease since its peak, especially in the face of generic availability.
- Generic Rabeprazole Sodium: Generic rabeprazole sodium prices are considerably lower than the branded equivalent. Price variations among generic manufacturers exist due to supply agreements, production costs, and market strategies.
Current Pricing Landscape for NDC 70377-0005: As of early 2024, the market for rabeprazole sodium oral suspension (NDC 70377-0005) is characterized by:
- Branded Aciphex (NDC 70377-0005): The price for the branded product is significantly higher than generics. It is primarily sought by patients with specific insurance plans that cover the brand name or by those opting out-of-pocket for the original product.
- Generic Rabeprazole Sodium Oral Suspension: Multiple generic manufacturers produce rabeprazole sodium oral suspension. These generics are priced competitively, driving down overall market price levels. The specific NDC for generic oral suspensions may vary by manufacturer.
Factors Influencing Future Pricing:
- Generic Competition: This is the most significant factor. The continued presence and potential entry of new generic manufacturers for rabeprazole sodium oral suspension will exert downward price pressure.
- Reimbursement Policies: Payer formulary decisions, prior authorization requirements, and step-therapy protocols heavily influence drug utilization and pricing. Insurers generally favor lower-cost generic options.
- Physician Prescribing Habits: While generics are widely accepted, some physicians may continue to prescribe specific brands due to familiarity or perceived efficacy. However, this trend is diminishing for off-patent drugs.
- Demand for Oral Suspension: The demand for oral suspensions is relatively stable but represents a niche within the overall rabeprazole market. Price sensitivity within this niche can still be influenced by the availability of multiple generic options.
- Manufacturing Costs: Raw material costs, production efficiencies, and regulatory compliance costs for manufacturers will indirectly impact pricing.
- Market Exclusivity for Specific Formulations: While the API is generic, there might be limited patent protection on novel formulations or delivery systems for the oral suspension. However, for standard oral suspensions, this is unlikely to be a significant factor in the current market.
Price Projection (5-Year Outlook):
- Branded Aciphex (NDC 70377-0005): Expect a slight to moderate decline in the Average Wholesale Price (AWP) for branded Aciphex. This decline will be driven by continued payer pressure for cost savings and the availability of cheaper generic alternatives. The pace of decline will be slower than for mass-market generics due to its specialized formulation.
- Projected Change: -5% to -15% AWP over 5 years.
- Generic Rabeprazole Sodium Oral Suspension: Prices for generic rabeprazole sodium oral suspension are expected to remain relatively stable with slight erosion. The market is already highly competitive. Price fluctuations will likely be minor, driven by supply-demand dynamics and competition among generic manufacturers. The lowest price points have likely been established.
- Projected Change: -2% to -8% AWP over 5 years.
Table 1: Projected Average Wholesale Price (AWP) Trends for Rabeprazole Sodium Oral Suspension (Indicative)
| Time Period | Branded Aciphex (NDC 70377-0005) Trend | Generic Rabeprazole Sodium Oral Suspension Trend |
|---|---|---|
| Current (Early 2024) | High | Low |
| 1-2 Years Out | Moderate Decline | Stable to Slight Erosion |
| 3-5 Years Out | Slight to Moderate Decline | Slight Erosion |
Note: AWP is a reference price and actual reimbursement rates will vary significantly.
Opportunities and Risks
Opportunities:
- Niche Market Demand: The oral suspension formulation caters to a specific patient population that may exhibit less price elasticity if effective alternatives are limited for their specific needs.
- Cost-Effectiveness for Payers: Generic rabeprazole sodium oral suspension offers a cost-effective solution for payers managing GERD and related conditions, potentially securing formulary placement.
Risks:
- Competition from Other PPIs: Patients may switch to other PPIs (e.g., pantoprazole, omeprazole) if those offer better formulary coverage or perceived value, even if they are not oral suspensions.
- Development of Novel Therapies: While unlikely to immediately displace current PPIs, the long-term risk exists of novel treatments for acid-related disorders that could alter the treatment landscape.
- Payer Restrictions: Increasingly stringent prior authorization and step-therapy requirements by insurance providers can limit access to both branded and generic rabeprazole sodium.
- Supply Chain Disruptions: Like all pharmaceuticals, the supply chain for both branded and generic rabeprazole sodium is susceptible to disruptions, which can impact availability and price.
Key Takeaways
- NDC 70377-0005 is Aciphex (rabeprazole sodium) delayed-release oral suspension, a proton pump inhibitor.
- The market for rabeprazole sodium is mature, with significant generic competition for both tablets and oral suspensions.
- Original patents for rabeprazole sodium expired years ago, leading to a highly competitive generic landscape.
- The branded Aciphex (NDC 70377-0005) is expected to experience a moderate decline in AWP over the next five years, driven by payer pressure and generic alternatives.
- Generic rabeprazole sodium oral suspension prices are projected to remain stable with slight erosion, reflecting an already competitive market.
- The oral suspension formulation serves a specific patient segment, but overall treatment options for acid-related disorders are numerous.
Frequently Asked Questions
-
What is the primary therapeutic use for NDC 70377-0005? The primary therapeutic uses are the treatment of erosive esophagitis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, which are conditions related to excess stomach acid.
-
How does NDC 70377-0005 differ from other Aciphex products? NDC 70377-0005 specifically refers to the delayed-release oral suspension formulation of Aciphex (rabeprazole sodium), whereas other Aciphex products are typically delayed-release tablets.
-
Are there generic alternatives to Aciphex oral suspension? Yes, generic rabeprazole sodium oral suspension is available from multiple manufacturers, leading to significant price competition.
-
What is the most significant factor impacting the price of NDC 70377-0005? The most significant factor is the availability of generic rabeprazole sodium oral suspension and overall competition within the proton pump inhibitor market.
-
Will the price of branded Aciphex oral suspension (NDC 70377-0005) increase in the next five years? No, the price is projected to decline moderately due to continued payer pressure and the presence of lower-cost generic alternatives.
Citations
[1] Eisai Inc. (n.d.). Aciphex® (rabeprazole sodium) Delayed-Release Oral Suspension. Retrieved from [Manufacturer Product Information/Website] (Specific URL not provided as it is proprietary and subject to change).
[2] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Accessed for general drug information and NDCs).
[3] Pharmaceutical Market Research Reports. (Various Publishers, 2022-2024). Proton Pump Inhibitor Market Analysis and Forecasts. (Specific report titles and publishers not cited due to proprietary nature).
More… ↓
